EEG Biomarkers for Alzheimer's Disease

Quantitative electroencephalography (qEEG) provides non-invasive, cost-effective biomarkers for Alzheimer's disease detection and monitoring. EEG alterations occur early in the disease process and correlate with cognitive decline. This page covers EEG biomarkers across different frequency bands, event-related potentials, and their clinical applications.

Overview

EEG changes in AD reflect: [@cassani2018]

• Neuronal loss — reduced cortical activity
• Synaptic dysfunction — altered connectivity
• Network disruption — changed synchronization patterns

Quantitative electroencephalography (qEEG) provides non-invasive, cost-effective biomarkers for Alzheimer's disease detection and monitoring. EEG alterations occur early in the disease process and correlate with cognitive decline. This page covers EEG biomarkers across different frequency bands, event-related potentials, and their clinical applications.

Overview

EEG changes in AD reflect: [@cassani2018]

• Neuronal loss — reduced cortical activity
• Synaptic dysfunction — altered connectivity
• Network disruption — changed synchronization patterns

• Slowing of background activity — increased delta/theta, decreased alpha/beta
• Reduced coherence — disrupted cortical connectivity
• Event-related potential (ERP) abnormalities — impaired cognitive processing

Frequency Band Biomarkers

Delta Band (0.5-4 Hz)

| Parameter | Early AD | Moderate AD | Controls | [@papaliagkas2011]
|-----------|----------|-------------|----------| [@ruzzoli2019]
| Delta power | ↑ 20-50% | ↑ 50-100% | Baseline | [@stam2009]
| Temporal delta | ↑ 30-60% | ↑ 80-150% | Low | [@gmez2013]

• Clinical significance: Correlates with disease severity
• [Babiloni et al., EEG delta in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32051234/)

Theta Band (4-8 Hz)

| Parameter | Early AD | Moderate AD | Controls | [@jelic2000]
|-----------|----------|-------------|----------| [@huang2020]
| Theta power | ↑ 30-70% | ↑ 80-150% | Baseline | [@kobayashi2005]
| Frontal theta | ↑ 50-100% | ↑ 100-200% | Low | [@kim2012]

• Diagnostic value: Strongest discriminator between AD and controls
• Sensitivity: 70-85%, Specificity: 75-90%
• [Cassani et al., EEG theta for AD detection (2018)](https://pubmed.ncbi.nlm.nih.gov/30122243/)

Alpha Band (8-12 Hz)

| Parameter | Early AD | Moderate AD | Controls | [@zhou2016]
|-----------|----------|-------------|----------|
| Alpha power | ↓ 20-40% | ↓ 40-60% | Baseline |
| Alpha frequency | ↓ 0.5-1.5 Hz | ↓ 1-2 Hz | 10 Hz |
| Posterior alpha | ↓ 30-50% | ↓ 50-70% | Highest |

• Key marker: Posterior alpha slowing
• [Moretti et al., Alpha alterations in MCI/AD (2009)](https://pubmed.ncbi.nlm.nih.gov/19327642/)

Beta Band (12-30 Hz)

| Parameter | Early AD | Moderate AD | Controls |
|-----------|----------|-------------|----------|
| Beta power | ↓ 10-30% | ↓ 30-50% | Baseline |
| Beta coherence | ↓ 15-25% | ↓ 30-40% | Normal |

• Clinical relevance: Associated with cognitive performance

Gamma Band (30-100 Hz)

| Parameter | AD vs. Controls | Notes |
|-----------|-----------------|-------|
| Gamma power | ↓ 20-40% | Impaired cortical processing |
| Gamma coherence | ↓ 15-30% | Disrupted integration |

• Emerging marker: May reflect specific therapeutic targets

Event-Related Potentials (ERPs)

P300 (P3) Component

| Parameter | AD | MCI | Controls |
|-----------|-----|-----|----------|
| P3 latency | ↑ 20-50 ms | ↑ 10-20 ms | Baseline |
| P3 amplitude | ↓ 20-40% | ↓ 10-20% | Normal |

• Clinical use: Cognitive assessment, disease progression
• Sensitivity: 65-80%, Specificity: 70-85%
• [Papaliagkas et al., P300 in Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21964529/)

N200 Component

• Abnormalities in AD: Reduced amplitude, delayed latency
• Value: Differentiates AD from other dementias

Mismatch Negativity (MMN)

• Reduced amplitude in AD
• Correlates with auditory memory dysfunction
• [Ruzzoli et al., MMN in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30647023/)

Coherence and Connectivity

Interhemispheric Coherence

| Band | AD vs. Controls | Regional Pattern |
|------|-----------------|------------------|
| Alpha | ↓ 20-35% | Posterior regions |
| Beta | ↓ 15-25% | Parietal-occipital |
| Theta | Variable | Frontal increase |

Intrahemispheric Connectivity

• Reduced long-range connectivity in AD
• Preserved short-range connections in early stages
• [Stam et al., EEG coherence in Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19328867/)

Quantitative EEG Metrics

Spectral Entropy

• Reduced in AD, particularly in posterior regions
• Correlates with MMSE scores (r = 0.6-0.7)
• [Gómez et al., Spectral entropy in AD (2013)](https://pubmed.ncbi.nlm.nih.gov/23875023/)

Peak Alpha Frequency (PAF)

| Group | Mean PAF |
|-------|----------|
| Controls | 10.2 Hz |
| MCI | 9.3 Hz |
| Mild AD | 8.7 Hz |
| Moderate AD | 8.1 Hz |

• Decline rate: ~0.5 Hz per disease stage

Slowing Index

• Formula: (Delta + Theta) / (Alpha + Beta)
• AD vs. Controls: 2-4x elevation
• Sensitivity: 75-85%

Resting State Patterns

Eyes-Closed Resting State

• Posterior alpha reduction — most consistent finding
• Increased theta — especially temporal regions
• Normal posterior dominant rhythm argues against AD

Eyes-Open Resting State

• Reduced alpha reactivity to eyes opening
• Increased frontal theta — less specific to AD

Mild Cognitive Impairment (MCI) Conversion Predictors

| EEG Marker | Conversion Prediction | Evidence |
|------------|----------------------|----------|
| Elevated theta power | 2-3x higher risk | Strong |
| Reduced alpha power | 1.5-2x higher risk | Strong |
| Slowing index elevation | High predictive value | Moderate |
| P3 latency prolongation | Moderate predictive value | Moderate |

• [Jelic et al., EEG predictors of MCI conversion (2000)](https://pubmed.ncbi.nlm.nih.gov/11019774/)
• [Huang et al., EEG and MCI progression (2020)](https://pubmed.ncbi.nlm.nih.gov/32198765/)

Non-Western Population Studies

Japanese Populations

• [Kobayashi et al., qEEG in Japanese AD patients (2005)](https://pubmed.ncbi.nlm.nih.gov/15834921/)
• [Saito et al., EEG coherence in Japanese cohort (2014)](https://pubmed.ncbi.nlm.nih.gov/25001045/)

Korean Populations

• [Kim et al., EEG in Korean MCI/AD (2012)](https://pubmed.ncbi.nlm.nih.gov/23035182/)
• [Park et al., Quantitative EEG in Korean elderly (2018)](https://pubmed.ncbi.nlm.nih.gov/29598432/)

Chinese Populations

• [Zhou et al., EEG biomarkers in Chinese AD (2016)](https://pubmed.ncbi.nlm.nih.gov/27094837/)
• [Wang et al., Resting-state EEG in Chinese MCI (2019)](https://pubmed.ncbi.nlm.nih.gov/31630928/)

Regulatory Status and Accessibility

| Technology | FDA Status | Cost (USD) | Accessibility |
|------------|------------|------------|--------------|
| Standard EEG | Standard care | $200-500 | Clinical available |
| qEEG analysis | Cleared (some) | $300-700 | Specialist required |
| Portable EEG | Cleared | $100-300 | Home possible |
| High-density EEG (256+) | Research | $1,000+ | Research only |

Clinical Applications

Diagnostic Support

• Adjunctive to clinical evaluation
• Differential diagnosis: AD vs. LBD (LBD shows greater slowing)
• Baseline establishment for progression monitoring

Disease Monitoring

• Track progression via slowing index
• Treatment response — cholinesterase inhibitors may normalize EEG
• Clinical trial endpoint — EEG biomarkers in trials

Preclinical Screening

• Research use only currently
• Family history screening potential

Cross-References

• p-Tau Biomarkers
• [CSF Biomarkers](/diagnostics/csf-biomarkers)
• Digital Biomarkers for Alzheimer's
• Sleep Biomarkers for Alzheimer's
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

Quantitative EEG Analysis

Frequency Domain Analysis

Quantitative EEG (qEEG) analysis involves transforming raw EEG signals into frequency components:

• Delta band (0.5-4 Hz): Elevated in advanced AD, reflects cortical dysfunction
• Theta band (4-8 Hz): Increased in early AD, marker of cognitive decline
• Alpha band (8-12 Hz): Decreased alpha power correlates with disease severity
• Beta band (12-30 Hz): Reduced beta may indicate network disconnection

Spatial Analysis

Topographic mapping reveals spatial patterns:

• Posterior dominant alpha reduction
• Generalized theta increase
• Asymmetric patterns in early disease
• Hemispheric connectivity changes

Statistical Measures

Key qEEG metrics:

• Spectral edge frequency (SEF95)
• Peak alpha frequency (PAF)
• Relative band powers
• Coherence measurements
• Phase-locking value

Event-Related Potentials

P300 Component

P300 is a widely studied ERP in AD:

• P3a: Reduced amplitude in AD, reflects attention dysfunction
• P3b: Prolonged latency correlates with cognitive impairment
• Clinical utility for detecting early changes
• Longitudinal tracking potential

Other ERPs

Additional ERPs in AD research:

• N200: Impaired in AD, reflects discrimination processes
• mismatch negativity (MMN): Reduced in early AD
• contingent negative variation (CNV): Altered in dementia
• auditory oddball: Standard cognitive assessment

Spectral Analysis

Time-Frequency Analysis

Advanced spectral decomposition:

• Short-time Fourier transform (STFT)
• Wavelet transform analysis
• Stockwell transform
• Hilbert-Huang transform

Biomarkers from Spectral Analysis

Quantitative measures:

• Alpha slowing index
• Theta/alpha ratio
• Delta+theta/alpha+beta ratio
• Spectral entropy
• Decorrelation time

Non-Western Population Studies

Asian Populations

EEG studies in Asian cohorts:

• Japanese populations: Similar patterns to Western
• Chinese studies: Validation of biomarkers
• Korean research: Machine learning applications
• Cross-cultural considerations

Other Regions

• Latin American cohorts
• African population studies
• Middle Eastern research
• Resource-limited settings

Clinical Utility

Diagnostic Accuracy

EEG biomarker performance:

• Sensitivity: 70-85% for AD detection
• Specificity: 75-90% for differential diagnosis
• Positive predictive value
• Negative predictive value

Cost-Effectiveness

Economic considerations:

• Low cost compared to PET
• Portable equipment available
• Minimal training required
• Repeated assessment feasible

Integration with Other Modalities

Multi-modal approaches:

• EEG + MRI hybrid studies
• EEG + PET combinations
• Integration with blood biomarkers
• Machine learning classifiers

Comparison with Other Modalities

MRI

| Feature | EEG | MRI |
|---------|-----|-----|
| Temporal resolution | High | Low |
| Spatial resolution | Low | High |
| Cost | Low | High |
| Accessibility | High | Medium |
| Invasiveness | Non-invasive | Non-invasive |

PET

| Feature | EEG | PET |
|---------|-----|-----|
| Metabolic information | Indirect | Direct |
| Amyloid detection | No | Yes |
| Tau imaging | No | Yes |
| Cost | Low | High |
| Radiation | None | Present |

Blood Biomarkers

| Feature | EEG | Blood |
|---------|-----|-------|
| p-tau detection | No | Yes |
| Aβ detection | No | Yes |
| Accessibility | High | High |
| Cost | Low | Medium |

Longitudinal Changes

Disease Progression

EEG changes over time:

• Annual decline rates
• Stage-specific patterns
• Conversion markers (MCI to AD)
• Rapid progressors identification

Treatment Monitoring

Therapeutic response tracking:

• Cholinesterase inhibitor effects
• Novel disease-modifying therapies
• Biomarker-driven trials
• Personalized medicine

Machine Learning Applications

Feature Extraction

ML approaches in EEG:

• Deep learning architectures
• Support vector machines
• Random forest classifiers
• Convolutional neural networks

Validation Studies

• Cross-validation results
• External validation cohorts
• Multi-site studies
• Real-world performance

Regulatory Status

Clinical Adoption

Current status:

• Research use predominates
• Clinical guidelines
• Reimbursement issues
• Standardization efforts

Future Directions

• FDA cleared algorithms
• Point-of-care devices
• Telemedicine integration
• Companion diagnostics

References

[^### R
Stand- Samp- Artifact rejec### Signal Proce
Advanced preprocessing:

• Baseline correction
• Filtering (bandpass 0.5-- Re-referencin- ICA-ba- Bad channel i

Quality Control

Metrics for data quality:

• Signal-to-noi- Channel reliability
• Eye blink contamination
• Muscle artifact levels
• Recording duration adequacy

Emerging Technologies

High-Density EEG

Advances in electrode arrays:

• 128-256 channel systems
• Dry electrode systems
• Wireless recording
• Mobile EEG devices

Closed-Loop Systems

Real-time applications:

• Neurofeedback training
• Adaptive stimulation
• Seizure prediction
• Cognitive enhancement

Specific Applications

Early Detection

EEG for preclinical AD:

• Subtle changes in asymptomatic individuals
• Genetic risk carriers (APOE4)
• Longitudinal monitoring
• Risk stratification

Differential Diagnosis

EEG in distinguishing:

• AD vs. Lewy body dementia
• AD vs. frontotemporal dementia
• AD vs. vascular dementia
• Early-onset vs. late-onset AD

Research Protocols

Standard Protocols

Common paradigms:

• Eyes closed rest
• Eyes open rest
• Hyperventilation
• Photic stimulation
• Cognitive tasks

Novel Paradigms

Emerging protocols:

• Semantic memory tasks
• Working memory load
• Emotional processing
• Social cognition

References (Additional)